查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1718380

按治疗类型、运动障碍类型、给药途径、原因和患者照护环境分類的运动障碍市场 - 2025 年至 2030 年全球预测

Dyskinesia Market by Treatment Type, Dyskinesia Type, Route of Administration, Cause, Patient Care Settings - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计运动障碍市场规模在 2024 年将达到 24.2 亿美元，2025 年将达到 25.9 亿美元，2030 年将达到 37 亿美元，复合年增长率为 7.30%。

主要市场统计数据
基准年2024年 24.2亿美元
预计2025年 25.9亿美元
预测年份 2030 37亿美元
复合年增长率（%） 7.30%

在不断发展的医学领域，运动障碍仍然是重要的研究领域和重点。本报告深入研究了运动障碍市场，强调了其现状和未来潜力。首先，我们关注运动障碍的临床性质，这是一种以不自主的肌肉运动为特征的运动障碍，会影响患者的生活品质。该报告结合了深入的实证研究和策略市场分析，帮助医疗保健专业人员和决策者应对疾病带来的挑战。本报告研究了历史趋势、诊断的复杂性以及对综合治疗方案的迫切需求。透过清晰直接的分析，该报告为理解多方面的市场动态和各相关人员的作用奠定了基础。大量临床数据和新治疗模式的深刻见解强调了及时医疗干预和整体患者照护的重要性。该采用为后续各章提供了背景，鼓励读者探索市场转型和细分见解，为市场演变提供充分的说明。

改变运动障碍市场

近年来，在技术和医学研究快速进步的推动下，运动障碍市场正在转变。随着创新治疗通讯协定和改进的诊断技术的结合，这种情况发生了巨大变化，从而实现了更个人化和有效的治疗策略。临床突破以及全面的数据分析推动市场进入精准医疗成为治疗方法核心部分的阶段。传统方法正被以证据为导向、以患者为中心的方法所取代，这些方法不仅解决症状，也针对运动障碍的根本原因和细微差别。在这个新模式下，相关人员正在采用数位解决方案、远端医疗和增强型监控系统，这些共同促进了更灵活和更具适应性的护理框架。不断发展的监管标准和创意的临床试验设计正在推动人们更加重视收集新治疗方法的真实世界证据。这种持续的转变不仅加深了我们对运动障碍的理解，也刺激了新治疗方法的开发，确保市场保持活力并能满足患者的复杂需求。

市场前景及详细市场细分

市场透过广泛的细分而分散，为治疗策略和患者互动提供了深入的见解。当考虑治疗类型时，市场会透过非药理学的处置方法、药物治疗和手术干预进行审查。非药物治疗类别透过检查行为、物理治疗和復健通讯协定进一步细分，而药物治疗又细分为抗胆碱能药物、多巴胺调变器、GABA促效剂、NMDA 受体拮抗剂和 VMAT2 抑制剂等组。我们将透过评估切除手术和日益重要的深部脑部刺激疗法来分析手术治疗。此外，根据运动障碍的类型进行细分可以对诸如手足徐动症、舞蹈症、肌张力不全症相关运动障碍、肌阵挛性运动障碍、帕金森氏症运动障碍、痉挛性斜颈和迟发性等病理进行分类。透过区分静脉注射注射、输液、口服、皮下、经皮等，给药途径得到了进一步的改善。它也提供了一个全面的框架来理解运动障碍的根本原因，从药物引起的、遗传的、特发性的、代谢性的运动障碍到与神经退化性疾病相关的运动障碍。最后，市场根据病患照护环境进一步细分，包括居家照护、医院、研究机构、专科诊所、復健中心等。这种多方面的细分凸显了满足运动障碍患者多样化需求所需的复杂性和个人化方法。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 帕金森氏症和其他神经系统疾病的盛行率不断上升
      • 支持性监管政策和加快的医药品认证过程将推动运动障碍治疗市场的成长
      • 提高医疗专业人员和患者对运动障碍及其管理的认识
    • 限制因素
      • 治疗运动障碍的治疗和疗法费用高昂
    • 机会
      • 医院与学术医疗系统之间在运动障碍研究和治疗方面建立重要伙伴关係
      • 神经药理学和外科治疗方案的进步为治疗症状开闢了新的途径。
    • 任务
      • 管理与运动障碍治疗相关的副作用和併发症
  • 市场区隔分析
    • 治疗类型：针对运动障碍背后的生化途径的药物治疗的需求日益增加。
    • 患者照护环境：医院部署的多维策略凸显了客製化护理解决方案以满足不同病患需求的重要性
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

6. 运动障碍市场（依治疗类型）

  • 介绍
  • 非药理学的处置方法
    • 行为疗法
    • 物理治疗与復健
  • 药物治疗
    • 抗胆碱药物
    • 多巴胺调变器
    • GABA能促效剂
    • NMDA受体拮抗剂
    • VMAT2抑制剂
  • 手术治疗
    • 消融手术
    • 深部脑部刺激（DBS）

7. 运动障碍市场（依运动障碍类型）

  • 介绍
  • 手足徐动症
  • 舞蹈症
  • 肌张力不全症相关的运动障碍
  • 肌阵挛性运动障碍
  • 帕金森氏运动障碍
  • 痉挛性斜颈
  • 迟发性运动障碍

8. 依给药途径分類的运动障碍市场

  • 介绍
  • 静脉注射 (IV) 和输液
  • 口服
  • 皮下
  • 经皮

第九章运动障碍市场（按原因）

  • 介绍
  • 药物引起的运动障碍
  • 遗传性运动障碍
  • 特发性运动障碍
  • 代谢性运动障碍
  • 神经退化性疾病相关的运动障碍

10. 运动障碍市场（依患者照护环境）

  • 介绍
  • 居家医疗
  • 医院
  • 研究所
  • 专科诊所及復健中心

第 11 章：美洲运动障碍市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太运动障碍市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲运动障碍市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Addex therapeutics
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca
  • Bayer Corporation
  • Contera Pharma A/S
  • F. Hoffmann-La Roche Ltd
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group
  • Medtronic plc
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • SOM BIOTECH
  • Sun Pharmaceutical Industries Ltd
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Voyager Therapeutics, Inc.
  • Zydus Group
Product Code: MRR-535C6291879B

The Dyskinesia Market was valued at USD 2.42 billion in 2024 and is projected to grow to USD 2.59 billion in 2025, with a CAGR of 7.30%, reaching USD 3.70 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.42 billion
Estimated Year [2025] USD 2.59 billion
Forecast Year [2030] USD 3.70 billion
CAGR (%) 7.30%

In the evolving landscape of healthcare, the condition of dyskinesia remains a critical area of study and attention. This report offers an in-depth look at the dyskinesia market, providing clarity on its current state as well as future possibilities. The discussion begins with a focused analysis of the clinical nature of dyskinesia, a movement disorder characterized by involuntary muscle movements that affect patient quality of life. As medical professionals and decision-makers seek to address the challenges posed by this condition, the report delves into a blend of empirical research and strategic market analysis. The narrative examines historical trends, diagnostic complexities, and the pressing need for comprehensive treatment options. Through clear and direct analysis, the report lays the foundation for understanding the multifaceted market dynamics and the roles of various stakeholders. Rich insights drawn from vast clinical data and emerging treatment paradigms underscore the criticality of timely medical interventions and holistic patient care. This introductory segment establishes the background that frames the subsequent sections, encouraging readers to explore the transformative changes and granular segmentation insights that offer an informed perspective on market evolution.

Transformative Shifts in the Dyskinesia Market Landscape

Over recent years, the dyskinesia market has experienced a series of transformative shifts driven by rapid advancements in both technology and medical research. The landscape has been reshaped by the integration of innovative treatment protocols alongside improved diagnostic techniques, enabling more personalized and effective therapeutic strategies. Clinical breakthroughs, alongside comprehensive data analytics, have propelled the market into a phase where precision medicine is becoming central to treatment regimens. Traditional methodologies are giving way to evidence-based, patient-centric approaches that not only address the symptoms but also target the underlying causes and nuances of dyskinesia. In this new paradigm, stakeholders are embracing digital solutions, telemedicine, and enhanced monitoring systems that together contribute to more agile and adaptive treatment frameworks. With evolving regulatory standards and creative clinical trial designs, there is an increased emphasis on gathering real-world evidence on emerging therapies. This continuous transformation not only deepens the understanding of dyskinesia but also stimulates the development of novel interventions, ensuring that the market remains dynamic and responsive to the complex needs of patients.

Detailed Segmentation Insights for a Nuanced Market View

The market is dissected through extensive segmentation that provides a granular insight into treatment strategies and patient interactions. When considering treatment type, the market is examined across non-pharmacological approaches, pharmacological treatments, and surgical interventions. The non-pharmacological category is further nuanced by exploring behavioral therapy and physical therapy along with rehabilitation protocols, while pharmacological treatments are meticulously classified into groups that include anticholinergics, dopamine modulators, GABA agonists, NMDA receptor antagonists, and VMAT2 inhibitors. Surgical treatments are analyzed by evaluating both ablative surgery and the increasingly significant deep brain stimulation procedures. Further segmentation based on dyskinesia type allows for the categorization of conditions such as athetosis, chorea, dystonia-related dyskinesia, myoclonic dyskinesia, Parkinson's dyskinesia, spasmodic torticollis, and tardive dyskinesia. The route of administration offers another layer of sophistication by differentiating between intravenous and infusion-based methods, oral forms, subcutaneous delivery, and transdermal systems. Moreover, understanding the underlying causes-ranging from drug-induced, genetic, idiopathic, and metabolic dyskinesia to neurodegenerative disorder-associated dyskinesia-provides a comprehensive framework. Finally, the market is further segmented based on patient care settings, encompassing home care, hospitals, research institutes, and specialty clinics along with rehabilitation centers. This multidimensional segmentation highlights the complexity and tailored approaches necessary for addressing the diverse needs of the dyskinesia patient population.

Based on Treatment Type, market is studied across Non-Pharmacological Approaches, Pharmacological Treatments, and Surgical Treatments. The Non-Pharmacological Approaches is further studied across Behavioral Therapy and Physical Therapy & Rehabilitation. The Pharmacological Treatments is further studied across Anticholinergics, Dopamine Modulators, GABA Agonists, NMDA Receptor Antagonists, and VMAT2 Inhibitors. The Surgical Treatments is further studied across Ablative Surgery and Deep Brain Stimulation (DBS).

Based on Dyskinesia Type, market is studied across Athetosis, Chorea, Dystonia-Related Dyskinesia, Myoclonic Dyskinesia, Parkinson's Dyskinesia, Spasmodic Torticollis, and Tardive Dyskinesia.

Based on Route of Administration, market is studied across Intravenous (IV) & Infusion-Based, Oral, Subcutaneous, and Transdermal.

Based on Cause, market is studied across Drug-Induced Dyskinesia, Genetic Dyskinesia, Idiopathic Dyskinesia, Metabolic Dyskinesia, and Neurodegenerative Disorder-Associated Dyskinesia.

Based on Patient Care Settings, market is studied across Home Care, Hospitals, Research Institutes, and Specialty Clinics & Rehabilitation Centers.

Global Regional Insights Shaping Market Dynamics

Market performance and growth are highly influenced by regional variations that depict distinct healthcare approaches and regulatory environments. Analysis indicates that the Americas are witnessing a robust integration of advanced therapeutic practices combined with supportive health policies, which further drive market expansions. In regions classified under Europe, Middle East & Africa, there is an evident blend of established medical systems and emerging innovation, where strategic investments in research and clinical infrastructure are gradually transforming patient care delivery. The Asia-Pacific region, on the other hand, presents a dynamic landscape that is marked by rapid urbanization, increasing healthcare awareness, and substantial infrastructure modernization. These regions, together with their unique regulatory frameworks and investment climates, create a mosaic of opportunities and challenges that require adaptive strategies from both market entrants and longstanding industry players. The region-specific insights help in identifying where the market resilience is strongest, and where targeted efforts could yield expedient results, underpinning the strategic decisions made by industry stakeholders.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insightful Key Companies Driving Innovation

A close examination of the corporate domain reveals a competitive ecosystem characterized by both established multinationals and agile innovators. Industry leaders such as AbbVie Inc. and AstraZeneca have charted significant progress through their research initiatives, while organizations like Addex therapeutics and Amneal Pharmaceuticals, Inc. bring forward innovative perspectives that challenge traditional methodologies. Bayer Corporation, Contera Pharma A/S, and F. Hoffmann-La Roche Ltd are pivotal in driving breakthrough solutions that redefine treatment paradigms. Companies such as Lundbeck A/S and Lupin Limited complement these efforts with robust research frameworks and clinical expertise, strengthening the overall market fabric. Additionally, entities like Luye Pharma Group, Medtronic plc, and Mitsubishi Tanabe Pharma Corporation have carved out distinguished niches within surgical and non-surgical intervention spheres. Leaders including Neurocrine Biosciences, Inc., Novartis AG, and Pfizer Inc. continue to shape market dynamics with their diversified portfolios, while SOM BIOTECH, Sun Pharmaceutical Industries Ltd, and Supernus Pharmaceuticals, Inc. contribute actively to product innovation. Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Voyager Therapeutics, Inc., and Zydus Group also emerge as key players who are continuously pushing the boundaries of research, ensuring a competitive yet dynamic marketplace that fosters collaboration and sustainable growth.

The report delves into recent significant developments in the Dyskinesia Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Addex therapeutics, Amneal Pharmaceuticals, Inc., AstraZeneca, Bayer Corporation, Contera Pharma A/S, F. Hoffmann-La Roche Ltd, Lundbeck A/S, Lupin Limited, Luye Pharma Group, Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., SOM BIOTECH, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Voyager Therapeutics, Inc., and Zydus Group. Actionable Recommendations for Driving Industry Growth

For industry leaders striving to optimize their strategies in the dyskinesia market, several actionable recommendations emerge from this comprehensive analysis. First, it is essential to invest in integrated research and clinical trials that foster collaboration across multiple treatment categories. Focusing on the convergence of non-pharmacological, pharmacological, and surgical techniques can lead to optimized, patient-specific intervention pathways. Companies should leverage emerging technologies and data analytics to gain deeper insights into treatment efficacy and patient outcomes, thereby enabling more informed decision-making. Next, the importance of diversifying portfolio strategies cannot be overstated; incorporating a mix of traditional treatments along with innovative approaches such as deep brain stimulation can significantly enhance competitive positioning. Embracing a global strategy that takes into account regional nuances will be critical for market expansion. Collaborative partnerships with research institutes and clinical organizations can support accelerated innovation. Proactive engagement with regulatory bodies to streamline approval processes and facilitate market entry is also vital. Ultimately, industry leaders need to continuously re-evaluate and refine their strategic frameworks, ensuring that investments in research, development, and technology remain at the forefront of addressing the intricate challenges posed by dyskinesia.

Concluding Analysis of the Dyskinesia Market Trends

In summary, the dyskinesia market is undergoing significant transformation, marked by rapid innovation, comprehensive segmentation, and diverse regional trends. With an in-depth focus on technological advancements, clinical breakthroughs, and tailored treatment strategies, stakeholders are well-equipped to navigate the complexities of this evolving landscape. The expansive segmentation framework provides a nuanced understanding of treatment modalities, dyskinesia subtypes, routes of administration, underlying causes, and patient care settings, all of which culminate in a precise mapping of market opportunities and challenges. Regional insights reveal distinct growth patterns influenced by healthcare infrastructure and investment environments, while the competitive analysis underscores the pivotal role played by leading companies. Through a balanced approach that combines scientific research with strategic market positioning, this report offers a timely reflection on the dynamic trends that define the current market environment. The analysis not only provides a robust foundation for future technological and clinical advancements but also charts a course for sustainable growth, reaffirming the industry's commitment to enhancing patient outcomes and overall healthcare delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of Parkinson's disease and other neurological disorders
      • 5.1.1.2. Supportive regulatory policies and expedited drug approval processes fostering market growth for dyskinesia treatments
      • 5.1.1.3. Increasing awareness among healthcare professionals and patients about dyskinesia and its management
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and therapies for dyskinesia management
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant partnerships between hospital and a university health system for Dyskinesia research and treatment
      • 5.1.3.2. Advancements in neuropharmacology and surgical treatment options that are providing new avenues for managing dyskinesia symptoms
    • 5.1.4. Challenges
      • 5.1.4.1. Managing side effects and complications associated with dyskinesia treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Increasing need for pharmacological treatments targeting the biochemical pathways underlying dyskinetic movements.
    • 5.2.2. Patient Care Settings: Multi-dimensional strategies deployed across hospitals underscore the importance of customizing care solutions to meet the diverse needs of dyskinesia patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dyskinesia Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Approaches
    • 6.2.1. Behavioral Therapy
    • 6.2.2. Physical Therapy & Rehabilitation
  • 6.3. Pharmacological Treatments
    • 6.3.1. Anticholinergics
    • 6.3.2. Dopamine Modulators
    • 6.3.3. GABA Agonists
    • 6.3.4. NMDA Receptor Antagonists
    • 6.3.5. VMAT2 Inhibitors
  • 6.4. Surgical Treatments
    • 6.4.1. Ablative Surgery
    • 6.4.2. Deep Brain Stimulation (DBS)

7. Dyskinesia Market, by Dyskinesia Type

  • 7.1. Introduction
  • 7.2. Athetosis
  • 7.3. Chorea
  • 7.4. Dystonia-Related Dyskinesia
  • 7.5. Myoclonic Dyskinesia
  • 7.6. Parkinson's Dyskinesia
  • 7.7. Spasmodic Torticollis
  • 7.8. Tardive Dyskinesia

8. Dyskinesia Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous (IV) & Infusion-Based
  • 8.3. Oral
  • 8.4. Subcutaneous
  • 8.5. Transdermal

9. Dyskinesia Market, by Cause

  • 9.1. Introduction
  • 9.2. Drug-Induced Dyskinesia
  • 9.3. Genetic Dyskinesia
  • 9.4. Idiopathic Dyskinesia
  • 9.5. Metabolic Dyskinesia
  • 9.6. Neurodegenerative Disorder-Associated Dyskinesia

10. Dyskinesia Market, by Patient Care Settings

  • 10.1. Introduction
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Research Institutes
  • 10.5. Specialty Clinics & Rehabilitation Centers

11. Americas Dyskinesia Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dyskinesia Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dyskinesia Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. PCD Research and NATA co-fund grant to advance therapy for primary ciliary dyskinesia
    • 14.3.2. Teva neuroscience secures FDA approval of once-daily Austedo XR for enhanced management of tardive dyskinesia and Huntington chorea
    • 14.3.3. Connecticut Children's and UConn Health partner to launch state's only primary ciliary dyskinesia center
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Addex therapeutics
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. AstraZeneca
  • 5. Bayer Corporation
  • 6. Contera Pharma A/S
  • 7. F. Hoffmann-La Roche Ltd
  • 8. Lundbeck A/S
  • 9. Lupin Limited
  • 10. Luye Pharma Group
  • 11. Medtronic plc
  • 12. Mitsubishi Tanabe Pharma Corporation
  • 13. Neurocrine Biosciences, Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. SOM BIOTECH
  • 17. Sun Pharmaceutical Industries Ltd
  • 18. Supernus Pharmaceuticals, Inc.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd
  • 21. Voyager Therapeutics, Inc.
  • 22. Zydus Group

LIST OF FIGURES

  • FIGURE 1. DYSKINESIA MARKET MULTI-CURRENCY
  • FIGURE 2. DYSKINESIA MARKET MULTI-LANGUAGE
  • FIGURE 3. DYSKINESIA MARKET RESEARCH PROCESS
  • FIGURE 4. DYSKINESIA MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DYSKINESIA MARKET SIZE, BY CAUSE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL DYSKINESIA MARKET SIZE, BY CAUSE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DYSKINESIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DYSKINESIA MARKET DYNAMICS
  • TABLE 7. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON'S DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DYSKINESIA MARKET SIZE, BY DRUG-INDUCED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DYSKINESIA MARKET SIZE, BY GENETIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DYSKINESIA MARKET SIZE, BY IDIOPATHIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DYSKINESIA MARKET SIZE, BY METABOLIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DYSKINESIA MARKET SIZE, BY NEURODEGENERATIVE DISORDER-ASSOCIATED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 290. NORWAY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 298. POLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 303. QATAR DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. QATAR DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 306. QATAR DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 311. RUSSIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 313. RUSSIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 314. RUSSIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 322. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 333. SPAIN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 335. SPAIN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. SPAIN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 337. SPAIN DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 338. SPAIN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 341. SWEDEN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 342. SWEDEN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 343. SWEDEN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. SWEDEN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 345. SWEDEN DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 346. SWEDEN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 350. SWITZERLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 352. SWITZERLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 354. SWITZERLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 356. TUR